Reglan Tardive Dyskinesia Settlement: Understanding Arizona's Statute of Limitations

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Occupational Exposure Concern

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational heritage emphasized the importance of informed consent and awareness of potential adverse effects associated with prescription drugs. Within this context, the transition to occupational exposure concern begins with recognizing that certain medications, such as Reglan (metoclopramide), carry specific risks that require heightened vigilance. In mass production environments, where workers may be exposed to pharmaceutical compounds or where medication management is part of occupational health protocols, the focus shifts from general awareness to targeted risk assessment. The concern here is not about disease mechanisms but about the practical implications of exposure duration and the legal frameworks that govern accountability. For instance, in Arizona, the statute of limitations for claims related to Reglan and tardive dyskinesia introduces a time-sensitive dimension to occupational health monitoring. This pivot from general health education to occupational exposure concern underscores the need for systematic tracking of medication history and exposure timelines in workplace settings, ensuring that workers and employers alike understand the legal and health implications of prolonged use or accidental exposure.

Reglan and Tardive Dyskinesia: Medical Evidence and Risk Context

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the manufacturer advises using the drug for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, which can be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition may be partially or fully suppressed by continued metoclopramide use, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding treatment longer than 12 weeks, but if longer use is unavoidable, routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. This pharmacological action is consistent with the known adverse effects of other dopamine-blocking agents. The label warns that concomitant use of other drugs known to cause TD should be avoided, and Reglan should not be used in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms of TD occur, immediate discontinuation of Reglan is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Claims in Arizona

From a risk perspective, the adequacy of warnings regarding Reglan and TD is addressed by the boxed warning, which is the strongest safety communication required by the FDA. The warning explicitly states the risk of TD, its potential irreversibility, and the importance of limiting treatment duration. However, patients who developed TD after prolonged use may argue that the warnings were insufficient or that prescribers did not adequately communicate the risks. Settlement-related considerations for affected patients in Arizona would involve evaluating the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Arizona, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, this timeline can be complex because the condition may develop gradually and may not be immediately recognized as drug-related. The latency period between exposure to Reglan and the onset of TD symptoms can vary, with some patients experiencing symptoms after months or years of use. The label notes that risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who used Reglan for extended periods beyond the recommended 12-week limit may have a stronger basis for claims, particularly if they were not adequately monitored for TD. Settlements in Reglan TD cases have been reached in multidistrict litigation, but individual state laws, including Arizona's statute of limitations, will affect eligibility. Patients should be aware that the clock for filing a claim typically starts when they knew or should have known that their TD was caused by Reglan. Medical records documenting the timing of Reglan use, onset of symptoms, and diagnosis of TD are critical for establishing the timeline. The label's warning that TD may be masked by continued metoclopramide use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) adds complexity, as patients may not have recognized the connection until after discontinuing the drug. In summary, Reglan's association with TD is well-documented in FDA labeling, with clear guidance on limiting treatment duration and monitoring. For Arizona patients considering legal action, the statute of limitations is a key factor, and the timeline between exposure and documented harm must be carefully assessed. Evidence of prolonged use beyond 12 weeks, lack of monitoring, or inadequate warnings may support claims. Patients should consult with a legal professional experienced in pharmaceutical litigation to evaluate their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Arizona?

In Arizona, the statute of limitations for personal injury claims, including those related to prescription drug injuries like tardive dyskinesia from Reglan, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline can be complex because TD may develop gradually and may not be immediately recognized as drug-related. Patients should consult with a legal professional to evaluate their specific circumstances.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine D2 receptor antagonism in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent involuntary movements. The risk increases with longer treatment duration and higher cumulative doses, as noted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.